Adjunctive vagus nerve stimulation for treatment-resistant bipolar disorder: managing device failure or the end of battery life

Pardo, José V.

doi:10.1136/bcr-2015-213949

Cited by 5 publications

(4 citation statements)

References 14 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was a single‐center study with the inherent limitations of retrospective studies and telephone surveys and included only 10 patients due to the relatively small number of PWE with RNS implants who experienced battery failure for a significant amount of time 14 . However, our numbers are similar to those reported in previous studies 11,15 . The survey response rate of 80% was comparable to or even superior to similar small patient population survey‐based studies with response rates between 65% and 79% 16–18 .…”

Section: Discussionsupporting

confidence: 51%

“…14 However, our numbers are similar to those reported in previous studies. 11,15 The survey response rate of 80% was comparable to or even superior to similar small patient population survey-based studies with response rates between 65% and 79%. [16][17][18] RNS ECoG data cannot be recorded during RNS battery depletion, limiting assessment of seizure control during this time to less reliable patient recall.…”

Section: Limitationsmentioning

confidence: 67%

See 1 more Smart Citation

Seizure control during spontaneous battery failure with responsive neurostimulation

Ward

Vallera

Ali

et al. 2023

Epileptic Disorders

View full text Add to dashboard Cite

Objective: We examined seizure control during spontaneous responsive neurostimulation (RNS) battery failure to investigate the persistent benefits of RNS in the absence of neurostimulation. We hypothesized that the loss of direct RNS does not immediately result in seizure worsening. Methods: Patients with RNS battery failure between August 2019 and December 2020 at a single institution were studied. During periods of battery depletion, the RNS device does not store any electrocorticography records, so we used a telephone-based survey and chart review to assess seizure control during battery depletion.Results: Eight of 10 eligible participants responded to the survey, with a mean duration of battery failure of 36 days (range: 10-219 days). During battery depletion, one patient reported decreased seizures and five reported no changes in seizure frequency. Only two patients reported increased seizure frequency. Significance:The benefits of RNS treatment may outlast the immediate effects of direct neurostimulation, lending support to the notion of persistent neuroplasticity. Larger studies should confirm our preliminary findings.

show abstract

Section: Discussionsupporting

confidence: 51%

Section: Limitationsmentioning

confidence: 67%

Seizure control during spontaneous battery failure with responsive neurostimulation

Ward

Vallera

Ali

et al. 2023

Epileptic Disorders

View full text Add to dashboard Cite

show abstract

“…VNS was first used to treat refractory epilepsy ( 34 ) and refractory depression ( 35 ). VNS could increase parasympathetic tone ( 36 ), which may counteract the effects induced by sympathetic activation and its associated NE release ( 37 ).…”

Section: Neuromodulation Methods For Afmentioning

confidence: 99%

Development of neuromodulation for atrial fibrillation: a narrative review

Yang,

Zou,

Wen

et al. 2024

J Thorac Dis

View full text Add to dashboard Cite

Background and Objective Atrial fibrillation (AF) is a prevalent clinical arrhythmia with a high incidence of disability and mortality. Autonomic nervous system (ANS) plays a crucial role in the onset and persistence of AF, and can lead to electrophysiological changes and alterations in atrial structure. Both animal models and clinical findings suggest that parasympathetic and sympathetic activity within the cardiac ANS could induce atrial remodeling and AF. Remodeling of the cardiac autonomic nerves is a significant structural basis for promoting AF. Given the challenges faced by conventional pharmacological and atrial ablation techniques in the treatment of AF, increasing attention has been paid to autonomic intervention strategies for AF. Current research has demonstrated that the frequency and severity of AF episodes can be significantly reduced by modulating the activity of ANS. ANS neuromodulation is expected to lead more effective and personalized treatment options for patients with AF. The objective of this review is to provide a broader perspective for future related studies by reviewing preclinical and clinical studies of neuromodulation methods for the treatment of AF, searching for relevant approaches to treat AF, as well as identifying the strengths and weaknesses demonstrated by current relevant studies, and providing researchers with a broader overview of the latest neurological treatments for AF. Methods A narrative review was conducted on the literature on PubMed, WanFang data, and Google Scholar, including all relevant studies published until November 2023. Key Content and Findings In this review, we delve into the innervation of cardiac autonomic nerves, the role of the ANS in the development and maintenance of AF, and the current neuromodulation methods for AF treatment. These methods include stellate ganglion (SG) resection or ablation, vagus nerve stimulation (VNS), thoracic subcutaneous nerve stimulation (ScNS), renal denervation (RDN) therapy, ganglionated plexus (GP) ablation, and epicardial botulinum toxin or CaCl 2 injection. More and more research suggests that neuromodulation methods for the treatment of AF have broad prospects. Conclusions ANS plays a crucial role in AF development and maintenance through cardiac autonomic nerve remodeling. Modulating ANS activity can significantly reduce AF frequency and severity, offering more personalized treatment options. Current research on autonomic interventions for AF shows promise for more effective and personalized treatments.

show abstract

“…Over the next few years many devices will face battery depletion, particularly impacting neuropsychiatric patients for whom deep brain stimulation (DBS) and vagal nerve stimulation (VNS) were approved in the last two decades, and EOBL is estimated at 6-10 years [95]. Pardo described the issues that neuropsychiatric patients will have as they face EOBL, exampled by the case of a middle-aged patient with bipolar disorder who relapsed following EOBL of her device-raising the question of whether neuropsychiatric device EBOL should be treated as a psychiatric emergency [95]. Listening to the device vs. the patients Throughout these stories patient voices are consistently heard insisting there is something wrong with their device, to find themselves dismissed due to 'normal' findings from device interrogation.…”

Section: End Of Battery Life (Ebol) Pathologymentioning

confidence: 99%

21st century medicine and emerging biotechnological syndromes: a cross-disciplinary systematic review of novel patient presentations in the age of technology

Straw,

Rees,

Nachev

2023

BMC Digit Health

View full text Add to dashboard Cite

Background Biotechnological syndromes refer to the illnesses that arise at the intersection of human physiology and digital technology. Now that we experience health and illness through so much technology (e.g. wearables, telemedicine, implanted devices), the medium is redefining our expression of symptoms, the observable signs of pathology and the range of diseases that may occur. Here, we systematically review all case reports describing illnesses related to digital technology in the past ten years, in order to identify novel biotechnological syndromes, map out new causal pathways of disease, and identify gaps in care that have disadvantaged a community of patients suffering from these digital complaints. Methods PubMed, MEDLINE, Scopus, Cochrane Library and Web of Science were searched for case reports and case series that described patient cases involving biotechnological syndromes from 01/01/2012 to 01/02/2022. For inclusion the technology had to play a causative role in the disease process and had to be digital (as opposed to simple electronic). Results Our search returned 7742 articles, 1373 duplicates were removed, 671 met the criteria for full review and 372 were included in the results. Results were categorised by specialty, demonstrating that syndromes were most common in Cardiology (n = 162), Microbiology and Infectious Diseases (n = 36), and Emergency and Trauma (n = 26). Discussion The 372 unique patient cases demonstrated a range of severity from mild (e.g., injuries related to Pokemon Go) to moderate (e.g. pacemaker-generated rib fractures) and severe (e.g. ventilator software bugs causing cardiac arrest). Syndromes resulted from both consumer technology (e.g. gaming addictions) and medical technologies (e.g. errors in spinal stimulators). Cases occurred at both the individual level (e.g. faulty insulin pumps) and at the population level (e.g. harm from healthcare cyberattacks). Limitations This was a retrospective systematic review of heterogeneous reports, written in English, which may only reflect a small proportion of true prevalence rates in the population.

show abstract

Adjunctive vagus nerve stimulation for treatment-resistant bipolar disorder: managing device failure or the end of battery life

Cited by 5 publications

References 14 publications

Seizure control during spontaneous battery failure with responsive neurostimulation

Seizure control during spontaneous battery failure with responsive neurostimulation

Development of neuromodulation for atrial fibrillation: a narrative review

21st century medicine and emerging biotechnological syndromes: a cross-disciplinary systematic review of novel patient presentations in the age of technology

Contact Info

Product

Resources

About